ZA201108439B - 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES - Google Patents

1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES

Info

Publication number
ZA201108439B
ZA201108439B ZA2011/08439A ZA201108439A ZA201108439B ZA 201108439 B ZA201108439 B ZA 201108439B ZA 2011/08439 A ZA2011/08439 A ZA 2011/08439A ZA 201108439 A ZA201108439 A ZA 201108439A ZA 201108439 B ZA201108439 B ZA 201108439B
Authority
ZA
South Africa
Prior art keywords
imidazo
quinolinone derivatives
quinolinone
derivatives
Prior art date
Application number
ZA2011/08439A
Other languages
English (en)
Inventor
Pascal Furet
Frank Stephan Kalthoff
Robert Mah
Christian Ragot
Frederic Stauffer
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42697442&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201108439(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ZA201108439B publication Critical patent/ZA201108439B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA2011/08439A 2009-06-04 2011-11-17 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES ZA201108439B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18414109P 2009-06-04 2009-06-04
PCT/EP2010/057719 WO2010139731A1 (en) 2009-06-04 2010-06-02 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES

Publications (1)

Publication Number Publication Date
ZA201108439B true ZA201108439B (en) 2012-08-29

Family

ID=42697442

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2011/08439A ZA201108439B (en) 2009-06-04 2011-11-17 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES

Country Status (30)

Country Link
US (2) US8476294B2 (enExample)
EP (1) EP2438064A1 (enExample)
JP (1) JP5596137B2 (enExample)
KR (1) KR101445458B1 (enExample)
CN (1) CN102574845B (enExample)
AR (1) AR076949A1 (enExample)
AU (1) AU2010255727B2 (enExample)
BR (1) BRPI1010621A2 (enExample)
CA (1) CA2763821A1 (enExample)
CL (1) CL2011003052A1 (enExample)
CO (1) CO6470887A2 (enExample)
CR (1) CR20110608A (enExample)
CU (1) CU24064B1 (enExample)
DO (1) DOP2011000373A (enExample)
EA (1) EA020715B1 (enExample)
EC (1) ECSP11011500A (enExample)
GE (1) GEP20156267B (enExample)
IL (1) IL216452A0 (enExample)
MA (1) MA33332B1 (enExample)
MX (1) MX2011012943A (enExample)
NI (1) NI201100209A (enExample)
NZ (1) NZ596487A (enExample)
PE (1) PE20120224A1 (enExample)
SG (1) SG176572A1 (enExample)
TN (1) TN2011000626A1 (enExample)
TW (1) TWI464168B (enExample)
UA (1) UA106074C2 (enExample)
UY (1) UY32682A (enExample)
WO (1) WO2010139731A1 (enExample)
ZA (1) ZA201108439B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102010035744A1 (de) 2010-08-28 2012-03-01 Merck Patent Gmbh Imidazolonylchinoline
BR112013013837A2 (pt) * 2010-12-06 2016-09-13 Piramal Entpr Ltd derivados de substituição de imidazoquinolina
JO3003B1 (ar) 2011-01-14 2016-09-05 Lilly Co Eli مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor
WO2013071698A1 (zh) * 2011-11-17 2013-05-23 山东轩竹医药科技有限公司 三环类PI3K和/或mTOR抑制剂
WO2014141118A1 (en) * 2013-03-14 2014-09-18 Piramal Enterprises Limited Imidazo[4,5-c]quinoline derivatives and uses thereof
CN105121411B (zh) 2013-04-15 2017-10-10 杜邦公司 杀真菌酰胺
US9893299B2 (en) 2013-09-11 2018-02-13 Merck Patent Gmbh Heterocyclic compounds
CN104513254B (zh) 2013-09-30 2019-07-26 上海璎黎药业有限公司 稠合嘧啶类化合物、中间体、其制备方法、组合物和应用
JP6606428B2 (ja) * 2013-10-11 2019-11-13 国立大学法人 東京医科歯科大学 脊髄小脳変性症を予防又は治療するための薬剤
AU2014352463B2 (en) * 2013-11-20 2017-05-11 Beijing Forelandpharma Co. Ltd. Ketone derivatives of imidazoles, pharmaceutical combinations and uses thereof
NO2714752T3 (enExample) 2014-05-08 2018-04-21
MA40281B1 (fr) 2014-06-03 2018-11-30 Idorsia Pharmaceuticals Ltd Composés de pyrazole et leur utilisation en tant qu' agents de blocage des canaux calciques de type t
EP3277681B1 (de) 2015-04-02 2019-05-08 Merck Patent GmbH Imidazolonylchinoline und deren verwendung als atm kinase inhibitoren
GB201516504D0 (en) 2015-09-17 2015-11-04 Astrazeneca Ab Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
GB201519568D0 (en) * 2015-11-05 2015-12-23 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
CN110023312A (zh) 2016-10-13 2019-07-16 由卫生与公众服务部部长代表的美利坚合众国 阻止疟疾寄生虫传播的化合物和方法
EP3554490B1 (en) 2016-12-16 2022-02-16 Idorsia Pharmaceuticals Ltd Pharmaceutical combination comprising a t-type calcium channel blocker
EP3577099B1 (en) 2017-02-06 2024-01-24 Idorsia Pharmaceuticals Ltd A novel process for the synthesis of 1-aryl-1-trifluoromethylcyclopropanes
JOP20190209A1 (ar) * 2017-03-16 2019-09-12 Astrazeneca Ab مركبات إيميدازو [ 4، 5-c ] كينولين-2-أون ديوترومية واستخدامها في علاج السرطان
JP7569688B2 (ja) 2017-12-22 2024-10-18 ハイバーセル，インコーポレイテッド ホスファチジルイノシトールリン酸キナーゼ阻害剤としてのアミノピリジン誘導体
TW202112767A (zh) 2019-06-17 2021-04-01 美商佩特拉製藥公司 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物
CN116574099A (zh) * 2019-09-23 2023-08-11 南京征祥医药有限公司 磷酸二酯酶抑制剂及用途
CA3184212C (en) * 2020-09-21 2024-11-05 Wei Zhong 1-(3,3-DIFLUOROPIPERIDIN-4-YL)-IMIDAZO[4,5-C]QUINOLEIN-2-ONE SUBSTITUTE COMPOUNDS WITH THE ABILITY TO CROSS THE BLOOD-BRAIN BARRIER
CN115136336A (zh) * 2021-01-26 2022-09-30 京东方科技集团股份有限公司 量子点发光器件、显示装置和制作方法
CN116768928A (zh) * 2023-06-15 2023-09-19 上海毕臣生化科技有限公司 一种3-叔丁基-5-硼酸酯基吡啶的合成方法
CN117384154A (zh) * 2023-09-04 2024-01-12 广州医科大学 一种吡咯并喹啉酮化合物、合成方法及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0211649D0 (en) 2002-05-21 2002-07-03 Novartis Ag Organic compounds
AR046845A1 (es) 2003-11-21 2005-12-28 Novartis Ag Derivados de 1h-imidazo[4,5-c]quinolina para tratamiento de enfermedades dependientes de las proteino-quinasas
BRPI0416801A (pt) 2003-11-21 2007-01-09 Novartis Ag derivados de 1h-imidazoquinolina como inibidores de proteìna sinase
AU2005284835A1 (en) 2004-09-14 2006-03-23 Novartis Vaccines And Diagnostics Inc. Imidazoquinoline compounds
GB0510390D0 (en) * 2005-05-20 2005-06-29 Novartis Ag Organic compounds
ES2429170T3 (es) 2005-11-04 2013-11-13 3M Innovative Properties Company 1H-Imidazoquinolinas sustituidas con hidroxilo y alcoxilo y métodos
GEP20125436B (en) 2006-11-20 2012-03-26 Novartis Ag Salts and crystal forms of 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile
US9370508B2 (en) * 2007-02-20 2016-06-21 Novartis Ag Imidazoquinolines as dual lipid kinase and mTOR inhibitors
RU2481838C2 (ru) * 2007-07-24 2013-05-20 Новартис Аг Применение имидазохинолинов для лечения заболеваний, зависимых от egfr, или заболеваний с приобретенной резистентностью к агентам, которые связываются с членами семейства egfr
US20090082387A1 (en) 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched nvp-bez234
CA2925257C (en) 2008-03-26 2019-04-30 Carlos Garcia-Echeverria 5imidazoquinolines and pyrimidine derivatives as potent modulators of vegf-driven angiogenic processes
US20110212053A1 (en) 2008-06-19 2011-09-01 Dapeng Qian Phosphatidylinositol 3 kinase inhibitors
EP2356120B1 (en) * 2008-09-30 2016-10-12 Pfizer Inc. Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions

Also Published As

Publication number Publication date
EP2438064A1 (en) 2012-04-11
MX2011012943A (es) 2012-01-27
AU2010255727A1 (en) 2011-12-08
CA2763821A1 (en) 2010-12-09
JP5596137B2 (ja) 2014-09-24
CO6470887A2 (es) 2012-06-29
CN102574845B (zh) 2015-09-02
CU24064B1 (es) 2014-12-26
JP2012528828A (ja) 2012-11-15
IL216452A0 (en) 2012-01-31
AR076949A1 (es) 2011-07-20
EA020715B1 (ru) 2015-01-30
CR20110608A (es) 2012-01-16
US20100317657A1 (en) 2010-12-16
TWI464168B (zh) 2014-12-11
UA106074C2 (uk) 2014-07-25
KR20120034710A (ko) 2012-04-12
WO2010139731A1 (en) 2010-12-09
US20140005163A1 (en) 2014-01-02
TN2011000626A1 (en) 2013-05-24
CU20110221A7 (es) 2012-03-15
CL2011003052A1 (es) 2012-08-31
NZ596487A (en) 2012-11-30
ECSP11011500A (es) 2012-01-31
SG176572A1 (en) 2012-01-30
US8476294B2 (en) 2013-07-02
KR101445458B1 (ko) 2014-10-07
CN102574845A (zh) 2012-07-11
MA33332B1 (fr) 2012-06-01
TW201102386A (en) 2011-01-16
NI201100209A (es) 2012-02-02
GEP20156267B (en) 2015-04-14
PE20120224A1 (es) 2012-04-04
AU2010255727B2 (en) 2013-02-28
DOP2011000373A (es) 2011-12-31
UY32682A (es) 2011-01-31
EA201101704A1 (ru) 2012-07-30
BRPI1010621A2 (pt) 2016-06-21

Similar Documents

Publication Publication Date Title
ZA201108439B (en) 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES
AP2806A (en) 3H-imidazo[4,5-C] pyridine-6-carboxamides as anti-infammatory agents
IL212417A0 (en) Lipidated imidazoquinoline derivatives
IL224903A (en) Imidzo [c – 5,4] quinolines as DNA inhibitors
ZA201200646B (en) Lipidated oxoadenine derivatives
IL212285A0 (en) Azaindole derivatives
IL235745A (en) Annotated 2-Aminopyridine
ZA201206630B (en) Hetaryl-[1,8]naphthyridine derivatives
ZA201201125B (en) Pyridin-4-yl derivatives
LT2740476T (lt) Cis-tetrahidro-spiro(cikloheksan-1,1`-pirido[3,4-b]indol)-4-amino dariniai
IL211241A0 (en) 7-azaindole derivatives
ZA201107350B (en) Imidazo [2 1 b] [1, 3, 4] thiadiazole derivatives
EP2408303A4 (en) MORPHINANE DERIVATIVES HAVING HIGH ORAL BIOLOGICAL AVAILABILITY
IL222080B (en) 6-alkyl-thieno[2,3-c]quinolin-4(5h)-one derivatives
PL2513119T3 (pl) Pochodne 3,4,4a,10b-tetrahydro-1H-tiopirano-[4,3-c]izochinoliny
ZA201007136B (en) Pyridin-2-yl derivatives as immunomodulating agents
ZA201105014B (en) Dihydroquinolinone derivatives
EP2448934A4 (en) DERIVATIVES OF 2-CARBOXAMIDE-7-PIPERAZINYL-BENZOFURAN
IL212942A0 (en) Rifamycin derivatives
IL219603A0 (en) Imidazopyridine derivatives
IL218500A0 (en) Apogossypolone derivatives as anticaner agents
IL216062A0 (en) Novel isoquinoline derivatives
GB0918922D0 (en) Aminopyridine derivatives
IL206949A0 (en) 2-aminoquinoline derivatives
GB2476643B (en) 1,4-Dihydro-1,4-dioxonaphtalene derivatives as anticoagulants